Public Policy Evaluation: the Case of the Green Prescription
Condition(s) studied
Investigational drug(s) / intervention(s)
Consumption of organic vegetables: Consumption of organic vegetables or non-organic for control group (according to their usual habits) for 2 weeks
Study summary
Numerous studies have highlighted the harmful effects of pesticide exposure during the prenatal period. Food is one of the main vectors of exposure to pesticides, particularly glyphosate, which is the most widely used herbicide. Observational studies have highlighted their effects on health, but few interventional studies have been conducted to identify effective interventions to reduce or eliminate environmental risks. In 2022, the City of Strasbourg implemented the "Ordonnance Verte" (Green Prescription) program, giving all pregnant women in the city access to a weekly basket of organic and local vegetables for several months, as well as awareness-raising workshops on endocrine disruptors and healthy eating. The objective of this study is to assess whether this type of program reduces pregnant women's exposure to pesticides compared to women who continue to eat according to their usual habits. If conclusive, this type of assessment would play a key role in facilitating the rollout of similar initiatives on a larger scale and protecting the health of pregnant women and future children.
Eligibility
Primary outcome measure(s)
- Change in urinary pesticide concentrations over the two-week study period in the intervention group — Day 0 and at 2 weeks
Measured as the difference in pesticide levels before and after the intervention - Difference in urinary pesticide concentrations between the two groups — Day 0 and at 2 weeks
Measured as the difference in pesticide levels in intervention vs. control groups
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hôpitaux Universitaires de Strasbourg | Strasbourg | France | Recruiting |
More University Hospital, Strasbourg, France trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07234617 on ClinicalTrials.gov ↗ ← All trials in France